These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus. Folli F; Daniele G; Werner S; Kamath S; Munera JV; Abboud H; Fanti P Acta Diabetol; 2015 Oct; 52(5):897-903. PubMed ID: 25753172 [TBL] [Abstract][Full Text] [Related]
11. Glutamic acid decarboxylase autoantibodies and neurological disorders. Vianello M; Tavolato B; Giometto B Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283 [TBL] [Abstract][Full Text] [Related]
12. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity. Costa M; Saiz A; Casamitjana R; Castañer MF; Sanmartí A; Graus F; Jaraquemada D Clin Exp Immunol; 2002 Sep; 129(3):471-8. PubMed ID: 12197888 [TBL] [Abstract][Full Text] [Related]
13. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Rakocevic G; Raju R; Semino-Mora C; Dalakas MC Neurology; 2006 Sep; 67(6):1068-70. PubMed ID: 17000981 [TBL] [Abstract][Full Text] [Related]
14. Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I. Tuomi T; Björses P; Falorni A; Partanen J; Perheentupa J; Lernmark A; Miettinen A J Clin Endocrinol Metab; 1996 Apr; 81(4):1488-94. PubMed ID: 8636356 [TBL] [Abstract][Full Text] [Related]
15. An anti-GAD autoantibody-associated cerebellar syndrome case: a curable cause of ataxia. Dogan VB Neurol Sci; 2015 Oct; 36(10):1929-31. PubMed ID: 26058956 [No Abstract] [Full Text] [Related]
16. [Recurrent serositis as manifestation of autoimmune polyglandular syndrome type 2]. Fernández Fernández FJ; de la Fuente Aguado J; Pérez Fernández S; Hervás Abad E; Páramo Fernández C Rev Clin Esp; 2006 Sep; 206(8):410. PubMed ID: 16863634 [No Abstract] [Full Text] [Related]
17. Analysis of antibody reactivity against cysteine sulfinic acid decarboxylase, a pyridoxal phosphate-dependent enzyme, in endocrine autoimmune disease. Sköldberg F; Rorsman F; Perheentupa J; Landin-Olsson M; Husebye ES; Gustafsson J; Kämpe O J Clin Endocrinol Metab; 2004 Apr; 89(4):1636-40. PubMed ID: 15070923 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the humoral immune response to glutamic acid decarboxylase in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and/or type 1 diabetes. Ronkainen MS; Härkönen T; Perheentupa J; Knip M Eur J Endocrinol; 2005 Dec; 153(6):901-6. PubMed ID: 16322397 [TBL] [Abstract][Full Text] [Related]
19. Polyglandular autoimmune syndrome type III with a prevalence of cutaneous features. Capo A; Amerio P Clin Exp Dermatol; 2017 Jan; 42(1):61-63. PubMed ID: 27859474 [TBL] [Abstract][Full Text] [Related]
20. Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis. Al-Bukhari TA; Radford PM; Bouras G; Davenport C; Trigwell SM; Bottazzo GF; Lai M; Schwartz HL; Tighe PJ; Todd I Clin Exp Immunol; 2002 Oct; 130(1):131-9. PubMed ID: 12296864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]